Novo Nordisk Stock Crashes on Obesity Drug Data. It’s a Win for Eli Lilly.
Novo Nordisk has told the world it expects patients to lose “at least 25%” of their body weight on its experimental drug CagriSema. On Friday, Novo released the results of a large Phase 3 trial of the ...